FTSE 250 movers: Telecom Plus climbs as oil stocks slide
10th Oct 2014 15:13
Utility services group Telecom Plus said it is happy with market expectations for the full year after strong organic growth in the first half, causing shares to surge on Friday. The company said that the strong growth in both customers and service numbers seen at the start of the year accelerated in
Read moreHikma Pharmaceuticals drug put under restraining order
10th Oct 2014 12:29
Distribution of Hikma Pharmaceuticals' food and drug administration (FDA) approved colchicine 0.6mg capsules has been put under a temporary restraining order, the company announced on Friday. The order was granted to Takeda Pharmaceuticals, with litigation between the two companies expected to conti
Read moreFriday broker round-up UPDATE
26th Sep 2014 08:38
Balfour Beatty: Deutsche Bank ups target price from 245p to 270p upgrading to buy. Betfair: JP Morgan raises target price from 1050p to 1175p leaving its neutral rating unchanged. British Land: Societe Generale upgrades to buy with a target price of 780p. Dairy Crest: Investec cuts target price fr
Read moreHikma completes acquisition of Ben Venue manufacturing site
17th Sep 2014 12:12
Hikma Pharmaceuticals announced on Wednesday the completion of the acquisition for the Ben Venture Laboratories’ manufacturing site. Ben Ventures Laboratories is a subsidary of the Boehringer Ingelheim Pharmaceuticals Group. As agreed on 24 July, Hikma has now acquired ownership of all of the
Read moreSector movers: Astrazeneca boosts pharma stocks on Pfizer return hopes
21st Aug 2014 17:48
Astrazenca was leading the pharmaceuticals sector higher on Thursday on the back of speculation that US drug giant Pfizer could return with a fresh offer in the coming days. The reports lifted others in the sector higher in afternoon trading with peers such as Glaxosmithkline, Hikma and BTG making
Read moreLondon midday: UK stocks advance as investors shrug off weak data
21st Aug 2014 12:01
- Mining stocks fall as Chinese data weakens - Eurozone PMIs and UK retail sales disappoint - US data, Jackson Hole ahead techMARK 2,810.76 +0.50% FTSE 100 6,772.04 +0.25% FTSE 250 15,797.15 +0.31% Falls in the heavyweight mining sector weren't enough to stop the FTSE 100 from advancing on Thursda
Read moreFTSE 250 movers: Ex-divi stocks and Balfour lead index lower
20th Aug 2014 13:57
Berkeley Group, Fidessa Group and Taylor Wimpey all dropped into the red after going ex-dividend on Wednesday. Balfour Beatty was in negative territory after rejecting another merger offer from rival Carillion, saying such a move would not be in shareholders' best interest. Tuesday's offer was the
Read moreHikma revenue lifted by strong injectables performance
20th Aug 2014 09:11
A strong performance by its injectables business helped drive first half revenue growth of 16% at pharmaceuticals manufacturer Hikma. The business delivered a 41% jump in turnover, lifting group revenue from $638m to $738m and the gross margin from 55.3% to 59.8%. A good performance was seen acr
Read moreSector movers: Shire and AZN lead pharma stocks lower on M&A risk
6th Aug 2014 14:13
The pharmaceutical sector dropped on Wednesday on the back of fears about risks to mergers and acquisitions (M&A) activity, with Shire sinking sharply. Concerns that stricter rules on so-called 'tax inversion' in the US could scupper Abbvie's £32bn takeover of London-listed Shire dented the latter'
Read moreFriday broker round-up UPDATE
1st Aug 2014 10:33
AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation. Avacta: Numis places both its target price and its buy recommendation under review. Barclays: Berenberg upgrades from sell to hold with a target price of 220p. Bodycote: UBS shifts target price f
Read moreHikma to purchase Ben Venue manufacturing site
24th Jul 2014 11:30
Hikma Pharmaceuticals confirmed its acquisition of the generic injectables manufacturing site owned by US group Ben Venue Laboratories. The deal, which follows an exclusivity arrangement inked in May, will form part of the previously announcement agreement to acquire Ben Venue Laboratories for $22
Read moreSector movers: Weak results, outlook from Glaxo sink pharma stocks
23rd Jul 2014 14:17
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read moreFriday broker round-up UPDATE
18th Jul 2014 07:55
Barclays: Credit Suisse cuts target price from 275p to 235p retaining a neutral rating. Barratt Developments: Liberum Capital reduces target price from 468p to 387p and downgrades to hold. Bellway: Liberum Capital reduces target price from 1900p to 1764p, while leaving its buy recommendation uncha
Read moreThursday broker round-up UPDATE
17th Jul 2014 11:07
Antofagasta: Canaccord Genuity cuts target price from 870p to 835p and maintains a hold recommendation. African Minerals: Canaccord Genuity reduces target price from 230p to 170p and keeps a buy recommendation. Ashmore Group: Goldman Sachs downgrades to neutral with a target price of 430p. Barcla
Read moreSector movers: Shire soars as M&A fever boosts pharma, health stocks
20th Jun 2014 13:56
News that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet
Read more